Tanzania: Presidential election campaign under way in Zanzibar

Denver weather: Warm, sunny and dry for most of the week

Sunshine and warm weather is in store for the Denver area Sunday, with high temperatures reaching the mid-80s.

The warm and dry weather will continue all week, with highs most days in the mid-80s and lows in the mid-50s, according to the National Weather Service at Boulder.

The region might see some mildly gusty winds on Sunday, Monday and Tuesday, and those winds are expected to calm down later in the week.

No significant rain is expected Sunday or through the rest of the week.

U.S. Won’t Back Israeli Annexation Before 2024: Report

Follow us @middleeast for more news on the region.

President Donald Trump’s administration promised the United Arab Emirates that the U.S. wouldn’t recognize an Israeli annexation of parts of the West Bank until January 2024 at the earliest, the Times of Israel reported, citing unidentified people with knowledge of the matter.

The time frame would cover most of Trump’s second term, if he is re-elected. The Trump administration is hoping to use the possibility of backing the annexation during the final year as leverage to bring the Palestinians to the negotiating table, the website said.

Kushner Says U.S. Got Assurances From Netanyahu on Annexation

The White House and UAE officials in Washington and New York declined to comment, the Times of Israel said.

The extension of sovereignty was part of the Trump administration’s Mideast peace plan, and Prime Minister Benjamin Netanyahu had said he would move forward with it as early as July 2020, albeit only with American support. As part of the normalization agreement last month between Israel and the UAE, the U.S. said the annexation was suspended, without stating for what period of time.

SoftBank Officials Revive Talks to Take Company Private: FT

In this article

SoftBank Group Corp. executives are reviving discussions about taking the technology company private, the Financial Times reported, citing people with direct knowledge of the matter.

The talks are driven by frustrations over the persistent discount in SoftBank’s $115 billion equity valuation compared with the value of its individual holdings, the Financial Times said. A number of fundamental changes to SoftBank’s long-term business strategy also accelerated the talks.

Internal opposition to a management buyout, however, remains strong, because there is strong prestige in Japan attached to being a listed company, the newspaper said.

SoftBank declined to comment to the paper.

SoftBank had briefly explored a take private with the support of activist hedge fund Elliott Management and Abu Dhabi state fund Mubadala, the FT reported in March. SoftBank is nearing a deal to sell its chipmaker Arm Ltd. to Nvidia Corp in a deal that could value Arm at about $40 billion in cash and stock, people familiar with the matter told Bloomberg.

What is the drug Remdesivir?

New York (CNN Business)Gilead Sciences will acquire biopharmaceutical company Immunomedics for $21 billion, the company announced on Sunday. The acquisition will expand Gilead’s portfolio of treatments for various types of cancer.

The deal with Immunomedics provides Gilead (GILD) with Trodelvy, an antibody drug for advanced triple-negative breast cancer. The drug was given accelerated FDA approval in April. Immunomedics will be acquired by $88 per share in cash — more than double the $42.25 at which shares traded on Friday’s close.
“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” Gilead Chairman and CEO, Daniel O’Day said in a statement. “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments.”

    The deal is anticipated to close in the fourth quarter of 2020, according to the companies. The dealwill be funded by $15 billion in cash on hand and roughly $6 billion in newly issued debt, Gilead said.

    Gilead to buy Immunomedics in $21B deal

    Vir Biotechnology CEO on partnership with GlaxoSmithKline and push for COVID antibody drug

    Barron’s Big Interview: Jack Otter is joined by George Scangos, Vir Biotechnology CEO.

    (Reuters) – Gilead Sciences Inc GILD.O will acquire biopharmaceutical company Immunomedics Inc IMMU.O for $21 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the companies said on Sunday in a statement.

    Continue Reading Below

    Gilead will buy Immunomedics for $88 per share in cash, according to the statement.

    GILEAD FILES US MARKETING APPLICATION FOR REMDESIVIR

    The transaction is expected to close in Q4 of 2020, the companies said.

    GET FOX BUSINESS ON THE GO BY CLICKING HERE

    WHO reports record one-day increase in global coronavirus cases, up over 307,000

    GENEVA (REUTERS) – The World Health Organisation reported a record one-day increase in global coronavirus cases on Sunday (Sept 13), with the total rising by 307,930 in 24 hours.

    The biggest increases were from India, the United States and Brazil, according to the agency’s website.

    Deaths rose by 5,537 to a total of 917,417.

    Tanzania: Presidential election campaign under way in Zanzibar

    One of the main issues is the status of Zanzibar’s union with mainland Tanzania.

    Campaigning is under way in Tanzania’s semi-autonomous state of Zanzibar for what is expected to be a fiercely contested presidential election next month.

    The result could trigger another potentially violent fallout between the governing party and the opposition following the disputed election five years ago.

    One of the main issues is the status of Zanzibar’s union with mainland Tanzania.

    Al Jazeera’s Catherine Soi reports from neighbouring Kenya.